Pharma & Biotech - Page 18

Alfasigma has announced plans to acquire Nordic Pharma from Sever Life Sciences in a deal worth an undisclosed sum, marking its latest international expansion move. The Italian drugmaker is purchasing Nordic Pharma,

Neurocrine Biosciences is pushing back against growing safety concerns surrounding Vykat XR, its rare disease drug acquired in a $2.9 billion buyout of Soleno Therapeutics last spring. A group of clinicians with

Amgen (AMGN) faces mounting pressure over its rare disease drug Tavneos after European regulators published detailed findings underpinning their decision to revoke its marketing authorisation. The European Commission formally confirmed last week

The global pharmaceutical cold chain market faces mounting pressure as high-value, temperature-sensitive medications become an increasingly significant share of drug pipelines worldwide. Biologics, vaccines, and cell and gene therapies require strict temperature

A federal appeals court has overturned the 2024 dismissal of a lawsuit accusing Bristol Myers Squibb of deliberately delaying approval of blood cancer drug Breyanzi. The U.S. Circuit Court of Appeals in

Pharmaceutical companies across the United States are facing mounting pressure from three distinct tariff tracks that are reshaping how the industry plans its domestic manufacturing footprint. The second episode of the Supply

Regeneron Genetics Center has spent 14 years building one of the most formidable genomic research operations in the pharmaceutical industry today. The center, known as RGC, serves as the genomic research branch

Novo Nordisk CEO Mike Doustdar is challenging the widely held investor view that the booming obesity drug market can only produce one clear winner. Speaking to Reuters in an interview published Thursday,

The pharmaceutical cold-chain logistics sector is undergoing significant transformation as industry expectations around product integrity continue to rise sharply. Maintaining precise temperature control throughout the supply chain has become one of the

Karyopharm Therapeutics is confronting a critical financial deadline, with a debt payment due in four weeks and cash reserves barely sufficient to survive into September. The Massachusetts-based biopharma reported its second quarter